Gastroenterology
Efficacy comparison of high-genetic barrier nucleos(t)ide analogues in treatment-naïve chronic hepatitis B patients: a network meta-analysis
Jaejun Lee, Ahlim Lee, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Hyun Yang
Korean J Intern Med. 2024;39(4):577-589. Published online June 13, 2024
Background/Aims: Four high-genetic barrier nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB), namely entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and besifovir dipivoxil maleate (BSV), have been established. The aim of this study is to investigate the ..
|
|
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Korean J Intern Med. 2022;37(6):1167-1175. Published online May 27, 2022
Background/Aims: To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting.
Methods: A total of 273 patients who received LDV/SOF therapy between May 2016 and February 2021 were consecutively enrolle..
|
|
Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
Ji Eun Ryu, Myeong Jun Song, Seok-Hwan Kim, Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Chul Nam, Hee Yeon Kim, Chang Wook Kim, Hyun Yang, Si Hyun Bae, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Soon Kyu Lee, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Korean J Intern Med. 2022;37(5):958-968. Published online August 19, 2022
Background/Aims: To evaluate the effectiveness and safety of direct acting antivirals (DAAs) available in chronic kidney disease (CKD) patients with hepatitis C virus (HCV) infection in Korea.
Methods: In a retrospective, multicenter cohort study, 362 patients were enrolled from 2015 to 2019. The e..
|
|
Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study
Jae Yoon Jeong, Dae Won Jun, Sol Ji Park, Joo Hyun Sohn, Sang Gyune Kim, Se Whan Lee, Soung Won Jeong, Moon Young Kim, Won Kim, Jae-Jun Shim, Hyoung Su Kim, Ki Tae Suk, Sang Bong Ahn
Korean J Intern Med. 2020;35(5):1074-1083. Published online November 12, 2019
Background/Aims: We aimed to assess the role of vitamin D supplementation in the response to pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment in patients with chronic hepatitis C (CHC).
Methods: Our study was a multi-center, randomized controlled trial in 11 hospitals. CHC patient..
|
|
Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice
Jeong Eun Song, Chang Hyeong Lee, Byung Seok Kim
Korean J Intern Med. 2019;34(4):802-810. Published online April 8, 2019
Background/Aims: The optimal management of chronic hepatitis B (CHB) patients with partial virologic response (PVR) to tenofovir disoproxil fumarate (TDF) remains unclear. We aimed to evaluate the long-term efficacy of prolonged TDF therapy in treatment-naïve CHB patients with PVR to TDF therapy in..
|
|
Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line
hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response
Ju-Yeon Cho, Won Sohn, Dong-Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Joon Hyeok Lee
Korean J Intern Med. 2017;32(4):636-646. Published online November 4, 2016
Background/Aims: Entecavir is a potent nucleoside analogue with high efficacy and barrier for resistance. We aimed to investigate the long-term efficacy and viral resistance rate of entecavir and explore the factors associated with virologic response, including quantitative hepatitis B surface anti..
|
|
|